A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Spectrum Pharmaceuticals, Inc
Start Date
December 6, 2017
End Date
November 30, 2023
Administered By
Duke Cancer Institute
Awarded By
Spectrum Pharmaceuticals, Inc
Start Date
December 6, 2017
End Date
November 30, 2023